东亚药业(605177) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was CNY 1,179,556,669.18, representing a year-on-year increase of 65.62%[23]. - The net profit attributable to shareholders for 2022 was CNY 104,423,862.82, an increase of 52.46% compared to the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 96.55% to CNY 93,749,071.41 in 2022[23]. - The basic earnings per share for 2022 rose by 53.33% to CNY 0.92[24]. - The weighted average return on equity increased to 5.80%, up by 1.86 percentage points from the previous year[25]. - The total assets at the end of 2022 were CNY 2,471,356,543.29, a 9.79% increase from the end of 2021[23]. - The company's equity attributable to shareholders increased by 4.65% to CNY 1,839.79 million compared to the previous year[35]. - The company's total revenue for 2022 was 406,318.19 million CNY, with a gross margin of 35.23%[104]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 2.9 per 10 shares, totaling RMB 32,944,000, subject to shareholder approval[5]. - The company will carry forward the remaining undistributed profits to future years[5]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[5]. - The company's cash dividend distribution is based on achieving positive distributable profits and receiving an unqualified audit report[176]. - The company has a history of cash dividend distribution, with a cash dividend of 3.5 RMB per 10 shares distributed in 2021, totaling 39,760,000 RMB, which accounted for 34.73% of the net profit for 2020[184]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[8]. - The company has established a strict internal control management system to enhance decision-making efficiency and ensure compliance and asset safety[191]. - The company received a standard unqualified opinion in the internal control audit report for 2022[192]. - The company has no significant deficiencies in internal control over subsidiaries during the reporting period[191]. Operational Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[8]. - The company faces risks from increasing competition in the raw materials and pharmaceutical intermediates market[135]. - The company is adapting to stricter regulatory requirements in the pharmaceutical industry, which may impact its operations[135]. - Environmental regulations are becoming stricter, increasing the pressure on the company to comply, which may lead to higher costs and impact profitability[140]. Research and Development - The company has over 30 invention patents and has been recognized as a national high-tech enterprise, indicating strong R&D capabilities[55]. - Research and development expenses increased by 20.53% to ¥44,947,984.62, indicating a continued investment in innovation[61]. - The company is focused on expanding its market presence through strategic partnerships and collaborations with downstream clients for product development[47]. - The company is investing in research and development to enhance its antibiotic portfolio, ensuring a strong market presence in the face of increasing competition[99]. Market Strategy and Expansion - The company plans to expand its production capacity for β-lactam antibiotics, which has been a significant driver of revenue growth[26]. - The company is focusing on expanding its market presence through strategic partnerships and potential acquisitions to enhance its competitive edge in the pharmaceutical industry[102]. - The company is committed to integrating high-end raw materials and formulations, aiming for a collaborative development of these products[131]. - The company is exploring potential mergers and acquisitions to strengthen its position in the pharmaceutical market[98]. Corporate Governance - The company has established a robust investor relations management system to maintain effective communication with investors and keep them informed about the company's operational developments[146]. - The company emphasizes respect for stakeholders, including customers, employees, suppliers, and the public, to promote sustainable development and enhance both economic and social benefits[146]. - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[144]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making and operations[145]. Environmental and Social Responsibility - The company invested 75.08 million yuan in environmental protection during the reporting period[194]. - The total non-methane hydrocarbon emissions for the year 2022 were 1.1012 tons, with an average emission concentration of 13.66 mg/m³[195]. - The total wastewater discharge for the year 2022 was 52,971.7436 tons, with a chemical oxygen demand average emission concentration of 209.95 mg/L[196]. - The company has no instances of exceeding pollutant discharge standards during the reporting period[196].